Gyre Therapeutics Inc
(GYRE)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2004 | |
| Cash Flows From Operating Activities | |
| Net Income | -24,025 |
| Depreciation Amortization | 766 |
| Accounts receivable | 334 |
| Other Working Capital | -1,518 |
| Other Operating Activity | -594 |
| Operating Cash Flow | $-25,037 |
| Cash Flows From Investing Activities | |
| Change In Deposits | 31,187 |
| PPE Investments | -622 |
| Investing Cash Flow | $30,565 |
| Cash Flows From Financing Activities | |
| Debt Issued | 3,250 |
| Debt Repayment | -731 |
| Common Stock Issued | 519 |
| Other Financing Activity | 32,900 |
| Financing Cash Flow | $35,938 |
| Beginning Cash Position | 11,609 |
| End Cash Position | 53,075 |
| Net Cash Flow | $41,466 |
| Free Cash Flow | |
| Operating Cash Flow | -25,037 |
| Capital Expenditure | -661 |
| Free Cash Flow | -25,697 |